# Regulatory Review Time of Vaccine Approvals in China Between 2005 and 2024 **Authors:** Yingtian Ding, Mengyuan Fu, Reshma Ramachandran, Luwen Shi, Joseph S. Ross, Xiaodong Guan PMC · DOI: 10.1001/jamanetworkopen.2025.18255 · JAMA Network Open · 2025-06-30 ## TL;DR This study analyzes how long it took for vaccines to be approved in China from 2005 to 2024. ## Contribution The study provides insights into regulatory timelines for vaccine approvals in China over two decades. ## Key findings - The study identifies trends in vaccine approval timelines. - It highlights variations in regulatory review durations across different periods. ## Abstract This cross-sectional study examines the regulatory review times for vaccine product applications submitted through China’s National Medical Products Administration over the past 2 decades. ## Full-text entities - **Diseases:** influenza (MESH:D007251), myelitis (MESH:D009187), diphtheria, pertussis, and tetanus (MESH:D013746), encephalitis (MESH:D004660), rabies (MESH:D011818), epidemic encephalitis (MESH:D004671), infectious diseases (MESH:D003141), Ebola virus disease (MESH:D019142), COVID-19 (MESH:D000086382), measles, mumps, and rubella (MESH:D009107), herpes zoster (MESH:D006562), MMR (MESH:C536143) - **Chemicals:** DPT (MESH:C059372), MAAs (-) - **Species:** Human adenovirus 5 (no rank) [taxon 28285], Human papillomavirus (species) [taxon 10566], Mycobacterium (genus) [taxon 1763], Homo sapiens (human, species) [taxon 9606] ## Full text _Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12210079/full.md ## Figures 1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12210079/full.md ## References 6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12210079/full.md --- Source: https://tomesphere.com/paper/PMC12210079